Abstract / Summary
Polypharmacy is common among cancer patients receiving chemotherapy due to the need for multiple supportive medications. This study assessed the prevalence of non-oncological polypharmacy and its association with quality of life (QoL) among adult cancer patients in Yemen. A cross-sectional study was conducted between 1st December 2025 and 23rd February 2026 at the National Oncology Centre in Sana’a, Yemen. Adult patients (≥18 years) receiving chemotherapy were recruited using convenience sampling. Data were collected through face-to-face interviews and medical record review. Polypharmacy was defined as the use of ≥5 non-oncological medications and excessive polypharmacy as ≥10 medications. QoL was assessed using the Arabic version of the EORTC QLQ-C30. Statistical analyses included descriptive statistics, independent-sample t -tests, and multiple linear regression using IBM SPSS Statistics version 27. Among 234 participants, 63.2% were female and 47.6% were aged 31–50 years. Polypharmacy was highly prevalent: 94.9% used ≥5 non-oncological medications and 56.4% ≥ 10. Mean global QoL was 47.9 (SD 26.7). Patients reported substantial financial difficulties (mean 82.3), fatigue (61.1), and pain (59.6). QoL did not differ significantly between excessive polypharmacy groups (mean difference −3.35; 95% CI −10.58 to 3.87; p = 0.361). In multivariable analyses, female gender independently predicted lower QoL (B = −10.13; 95% CI: −18.19 to −2.07; p = 0.014) and higher non-oncological medication use (B = 1.18; 95% CI: 0.25 to 2.10; p = 0.013). Age ≥ 51 years and illiteracy showed borderline associations with lower QoL, while all other variables, including excessive polypharmacy (≥10 non-oncological medications), were not significantly associated with QoL. Non-oncological Polypharmacy is highly prevalent among Yemeni cancer patients receiving chemotherapy. Although medication burden was substantial, it was not independently associated with QoL, whereas female gender predicted poorer outcomes.